Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Non-Current Debt (2020 - 2025)

Immunocore Holdings (IMCR) has disclosed Non-Current Debt for 6 consecutive years, with $393.1 million as the latest value for Q4 2025.

  • Quarterly Non-Current Debt rose 0.54% to $393.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $393.1 million through Dec 2025, up 0.54% year-over-year, with the annual reading at $393.1 million for FY2025, 0.54% up from the prior year.
  • Non-Current Debt hit $393.1 million in Q4 2025 for Immunocore Holdings, roughly flat from $392.6 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $438.1 million in Q2 2024 to a low of $46.3 million in Q4 2022.
  • Historically, Non-Current Debt has averaged $306.5 million across 5 years, with a median of $391.5 million in 2025.
  • Biggest five-year swings in Non-Current Debt: soared 714.42% in 2024 and later dropped 10.52% in 2025.
  • Year by year, Non-Current Debt stood at $50.2 million in 2021, then dropped by 7.67% to $46.3 million in 2022, then rose by 3.63% to $48.0 million in 2023, then skyrocketed by 714.42% to $391.0 million in 2024, then rose by 0.54% to $393.1 million in 2025.
  • Business Quant data shows Non-Current Debt for IMCR at $393.1 million in Q4 2025, $392.6 million in Q3 2025, and $392.1 million in Q2 2025.